ERBB2 and cancer: By combining the penetration and effector function of an antibody, our laboratory generated a small recombinant molecule termed Grababody 4D5scFv-ZZ by incorporating the Z-domain derived from Protein A into a 4D5scFv fusion protein, which could recruit circulating IgGs to regain ADCC and CDC activity targeting Her2-specific cancer cell lines.